株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

治験 (臨床試験) の世界市場:成長、動向、予測

Clinical Trials Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 390668
出版日 ページ情報 英文 117 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
治験 (臨床試験) の世界市場:成長、動向、予測 Clinical Trials Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 117 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、世界の治験 (臨床試験) 市場について分析し、市場の基本構造や促進・抑制要因、市場規模の動向見通し (今後6年間分)、相 (フェーズ) 別・治験計画別・地域別の詳細動向、市場競争環境 (昨今の資本取引の動きなど)、主要企業のプロファイル、今後の市場機会などについて調査しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場のダイナミクス

  • 市場概要
  • 市場促進要因
  • 市場抑制要因
  • 業界の求心力:ポーターのファイブフォース分析

第5章 市場区分

  • 相 (フェーズ) 別
    • 第I相
    • 第II相
    • 第IIII相
    • 第IV相
  • 設計 (計画) 別
    • 治療研究
      • ランダム化比較試験
        • 二重盲検ランダム化試験
        • 一重盲検ランダム化試験
        • 非盲検ランダム化試験
      • 適応的治験
      • 非ランダム化比較試験
    • 観察研究
      • コホート研究
      • 症例対照研究
      • 横断研究 (クロスセクション研究)
      • 地域相関研究 (生態学的研究)
  • 地域別
    • 北米 (米国、カナダ、メキシコ)
    • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
    • アジア太平洋地域 (中国、日本、インド、オーストラリア、韓国など)
    • 中東・アフリカ (湾岸協力会議 (GCC) 諸国、南アフリカなど)
    • 南米 (ブラジル、アルゼンチンなど)

第6章 競争環境

  • 企業プロファイル
    • Clinipace
    • Laboratory Corporation of America
    • Eli Lilly and Company
    • ICON PLC
    • Novo Nordisk AS
    • PAREXEL International Corporation
    • Pfizer Inc.
    • Pharmaceutical Product Development LLC
    • IQVIA
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Wuxi AppTec

第7章 市場機会と将来動向

目次
Product Code: 49264

Market Overview

The major factors found propelling the growth of the market include the high demand for clinical trials in emerging markets, high R&D spending of the pharmaceutical industry, an increasing prevalence of diseases, and the focus on rare diseases and multiple orphan drugs in the pipeline.

The market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions.

It has also been found that there are a large number of unmet clinical needs in emerging countries, due to the prevalence of infectious and tropical diseases in the region. Owing to these, a large number of the population participate in clinical trials to access high-quality healthcare free of cost. India and China have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity.

In addition, government initiatives have also motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field. It has also been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East and there is still very less development in the market.

Scope of the Report

As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, and III), which depends upon various factors. This process is not only expensive, but also time consuming, and requires expertise at all stages.

Key Market Trends

Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period

The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in emerging economies for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth.

North America has been Reported with the Largest Growth that is Expected to Follow the Same Trend over the Forecast Period

North America dominated the overall market, owing to the presence of big outsourcing firms and increasing R&D in the region. However, increasing R&D investments and an increasing demand for drug development are the major factors responsible for the market emergence in the United States.

Competitive Landscape

The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market's growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demand for Clinical Trials in the Emerging Markets
    • 4.2.2 High R&D Expenditure of the Pharmaceutical Industry
    • 4.2.3 Rising Prevalence of Diseases
    • 4.2.4 Focus on Rare Diseases and Multiple Orphan Drugs in the Pipeline
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Workforce Clinical Research
    • 4.3.2 Lower Healthcare Reimbursement in the Developing Countries
    • 4.3.3 Stringent Regulations for Patient Enrollment
  • 4.4 Porter' s Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Phase
    • 5.1.1 Phase I
    • 5.1.2 Phase II
    • 5.1.3 Phase III
    • 5.1.4 Phase IV
  • 5.2 By Design
    • 5.2.1 Treatment Studies
      • 5.2.1.1 Randomized Control Trial
      • 5.2.1.1.1 Double Blind Trial Randomized Trial
      • 5.2.1.1.2 Single Blind Trial Randomized Trial
      • 5.2.1.1.3 Non-blind Randomized Trial
      • 5.2.1.2 Adaptive Clinical Trial
      • 5.2.1.3 Non-randomized Control Trial
    • 5.2.2 Observational Studies
      • 5.2.2.1 Cohort Study
      • 5.2.2.2 Case Control Study
      • 5.2.2.3 Cross Sectional Study
      • 5.2.2.4 Ecological Study
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinipace
    • 6.1.2 Laboratory Corporation of America
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 ICON PLC
    • 6.1.5 Novo Nordisk AS
    • 6.1.6 PAREXEL International Corporation
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Pharmaceutical Product Development LLC
    • 6.1.9 IQVIA
    • 6.1.10 F. Hoffmann-La Roche Ltd
    • 6.1.11 Sanofi
    • 6.1.12 Wuxi AppTec

7 MARKET OPPORTUNITIES AND FUTURE TRENDS